James Crowe Jr. Archives
Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research
Dec. 1, 2020—James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.
Study identifies antibodies that block alphaviruses
Aug. 20, 2020—Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.
Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Antibodies eye Pacific Island “fever”
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
Antibody finding raises hopes for Marburg, COVID-19 treatments
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Antibody mixture may help block Ebola virus infection
Feb. 6, 2020—A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
Antibody isolated at VUMC found to halt dengue virus
Jan. 23, 2020—Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.
VUMC-led team isolates antibody that blocks bird flu
Dec. 12, 2019—VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.
Early effort to thwart chikungunya infection shows positive results
Sep. 13, 2019—Phase 1 trial results in new approach to combat the chikungunya
Partnership to help bring Zika virus therapy to clinic
Sep. 4, 2019—Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.
Vanderbilt vaccine pioneer James Crowe honored with major science prize
Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
